| Sign In to gain access to subscriptions and/or personal tools. |
A Standard Operating Procedure for Assessing Liquid Handler Performance in High-Throughput ScreeningGlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
Department of Assay Methodology Development, New Frontiers Science Park, Harlow, United Kingdom
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
Cheminformatics, King of Prussia, PA and Stevenage, United Kingdom
Department of Statistical Sciences, New Frontiers Science Park, Harlow, United Kingdom
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
Cheminformatics, King of Prussia, PA and Stevenage, United Kingdom
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom
Systems Research, King of Prussia, PA.
GlaxoSmithKline Pharmaceuticals, Department of Molecular Screening, King of Prussia, PA and Parque Tecnologico de Madrid, Spain and Stevenage, United Kingdom The thrust of early drug discovery in recent years has been toward the configuration of homogeneous miniaturized assays. This has allowed organizations to contain costs in the face of exponential increases in the number of screening assays that need to be run to remain competitive. Miniaturization brings with it an increasing dependence on instrumentation, which over the past several years has seen the development of nanodispensing capability and sophisticated detection strategies. To maintain confidence in the data generated from miniaturized assays, it is critical to ensure that both compounds and reagents have been delivered as expected to the target wells. The authors have developed a standard operating procedure for liquid-handling quality control that has enabled them to evaluate performance on 2 levels. The first level provides for routine daily testing on existing instrumentation, and the second allows for more rigorous testing of new dispensing technologies. The procedure has shown itself to be useful in identifying both method programming and instrumentation performance shortcomings and has provided a means to harmonizing instrumentation usage by assay development and screening groups. The goal is that this type of procedure be used for facilitating the exchange of liquid handler performance data across the industry.
Journal of Biomolecular Screening, Vol. 7, No. 6,
554-569 (2002) This article has been cited by other articles:
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||


